Breast cancer, screening and diagnostic tools: All you need to know
D Barba, A León-Sosa, P Lugo, D Suquillo… - Critical reviews in …, 2021 - Elsevier
Breast cancer is one of the most frequent malignancies among women worldwide. Methods
for screening and diagnosis allow health care professionals to provide personalized …
for screening and diagnosis allow health care professionals to provide personalized …
Theranostic advances in breast cancer in nuclear medicine
N Vahidfar, A Aghanejad, H Ahmadzadehfar… - International journal of …, 2021 - mdpi.com
The implication of 'theranostic'refers to targeting an identical receptor for diagnostic and
therapeutic purposes, by the same radioligand, simultaneously or separately. In regard to …
therapeutic purposes, by the same radioligand, simultaneously or separately. In regard to …
GRPR-targeting radiotheranostics for breast cancer management
A D'Onofrio, S Engelbrecht, T Läppchen… - Frontiers in …, 2023 - frontiersin.org
Breast Cancer (BC) is the most common cancer worldwide and, despite the advancements
made toward early diagnosis and novel treatments, there is an urgent need to reduce its …
made toward early diagnosis and novel treatments, there is an urgent need to reduce its …
Innovations in positron emission tomography and state of the art in the evaluation of breast cancer treatment response
L Castorina, AD Comis, A Prestifilippo… - Journal of Clinical …, 2023 - mdpi.com
The advent of hybrid Positron Emission Tomography/Computed Tomography (PET/CT) and
PET/Magnetic Resonance Imaging (MRI) scanners resulted in an increased clinical …
PET/Magnetic Resonance Imaging (MRI) scanners resulted in an increased clinical …
[HTML][HTML] Development and evaluation of 89Zr-trastuzumab for clinical applications
F Mohammadpour-Ghazi, H Yousefnia… - Asia Oceania Journal …, 2023 - ncbi.nlm.nih.gov
Objective (s): Due to the suitable physical characteristics of 89 Zr as a PET radionuclide and
affinity of Trastuzumab monoclonal antibody against HER2,[89 Zr] Zr-Trastuzumab was …
affinity of Trastuzumab monoclonal antibody against HER2,[89 Zr] Zr-Trastuzumab was …
[HTML][HTML] Cancer Theranostics: Pharmaceutical View
G Rajaram, A Alagaraswamy, M Subramanian, V Ravi - 2024 - intechopen.com
Cancer is undeniably a scary disease that leads to morbidity and mortality. With the state-of-
the-art advances, chemotherapy has made incredible strides, but the efficiency is still …
the-art advances, chemotherapy has made incredible strides, but the efficiency is still …
[PDF][PDF] Biological assessment and human absorbed dose estimation of [111In] In-DTPA-antiMUC1 as a radioimmunoconjugate for breast cancer imaging
H Yousefnia, S Zolghadri… - Iranian Journal of Nuclear …, 2022 - irjnm.tums.ac.ir
Introduction: The aim of this study was to evaluate the human organ absorbed dose of
[111In] In-DTPA-antiMUC1, as a newly developed radioimmunoconjugate. Methods:[111In] …
[111In] In-DTPA-antiMUC1, as a newly developed radioimmunoconjugate. Methods:[111In] …
Recent advancements in hematology: knowledge, methods and dissemination, part 2
J Corre, M Sabbah, F Schjesvold, AM Zeidan… - Hemato, 2021 - mdpi.com
Hemato | Free Full-Text | Recent Advancements in Hematology: Knowledge, Methods and
Dissemination, Part 2 Next Article in Journal Decades of Progress in Allogeneic Stem Cell …
Dissemination, Part 2 Next Article in Journal Decades of Progress in Allogeneic Stem Cell …
PET and SPECT imaging of tumor micro-environment: a systematic review of the last 20 years
Background: Molecular nuclear medicine, due to hybrid imaging camera systems and new
tailored radiopharmaceuticals, has been gained a clinical relevance for diagnosis, therapy …
tailored radiopharmaceuticals, has been gained a clinical relevance for diagnosis, therapy …
[引用][C] Desarrollo y evaluación de potenciales radiotrazadores para Imagenología Molecular en cáncer de mama
P Esquirós, M Pía - 2021 - Udelar. FQ